Experience with hepatitis A and B vaccines

American Journal of Medicine

Volumn 118, Issue 10 SUPPL., 2005, Pages 7-15

  Davis, Jeffrey P ^a  

^a WISCONSIN DIVISION OF PUBLIC HEALTH   (United States)

Author keywords

Combination vaccine; Efficacy; Hepatitis A; Hepatitis B; Immunogenicity; Vaccine

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; PEDIARIX; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ADULTHOOD; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; HEALTH STATUS; HEMODIALYSIS; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; UNITED STATES; VACCINATION;

EID: 27644553811     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.07.011     Document Type: Article

References (65)

1. B.P. Bell, S.M. Feinstone Hepatitis A vaccine S.A. Plotkin W.A. Orenstein Vaccines 4th ed. 2004 Saunders Company Philadelphia, PA 269 297
2. E. Mast, F. Mahoney, M. Kane, H. Margolis Hepatitis B vaccine S.A. Plotkin W.A. Orenstein Vaccines 4th ed. 2004 Saunders Company Philadelphia, PA 299 337
3. Centers for Disease Control and Prevention Hepatitis A W. Atkinson J. Hamborsky C. Wolfe Epidemiology and Prevention of Vaccine-Preventable Diseases 8th ed. 2004 Public Health Foundation Washington, DC 177 189
4. Centers for Disease Control and Prevention Hepatitis B W. Atkinson J. Hamborsky C. Wolfe Epidemiology and Prevention of Vaccine-Preventable Diseases 8th ed. 2004 Public Health Foundation Washington, DC 191 212
5. Centers for Disease Control and Prevention Prevention of hepatitis A through active or passive immunization recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 48 RR-12 1999 1 37
6. Havrix prescribing information 2005 GlaxoSmithKline Research Triangle Park, NC
7. Vaqta prescribing information 2005 Merck and Co., Inc Whitehouse Station, NJ
8. N.A. Halsey Limiting infant exposure to thimerosal in vaccines and other sources of mercury [editorial] JAMA 282 1999 1763 1766
9. P.A. Offit Preventing harm from thimerosal in vaccines [letter] JAMA 283 2000 2104 2105
10. Centers for Disease Control and Prevention Hepatitis B virus a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR Recomm Rep 40 RR-13 1991 1 19
11. Engerix-B prescribing information 2004 GlaxoSmithKline Research Triangle Park, NC
12. Recombivax HB prescribing information 2004 Merck and Co., Inc Whitehouse Station, NJ
13. American Academy of Pediatrics Hepatitis B L.K. Pickering Red Book 2003 Report of the Committee on Infectious Diseases 26th ed. 2003 American Academy of Pediatrics Elk Grove Village, IL 318 336
14. A. Werzberger, B. Mensch, B. Kuter A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children N Engl J Med 327 1992 453 457
15. D.R. Nalin, B.J. Kuter, L. Brown Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations an overview J Hepatol 18 suppl 2 1993 S51 S55
16. D. Shouval, Y. Ashur, R. Adler Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine effects of single and booster injections, and comparison to administration of immune globulin J Hepatol 18 suppl 2 1993 S32 S37
17. B.L. Innis, R. Snitbhan, P. Kunasol Protection against hepatitis A by an inactivated vaccine JAMA 271 1994 1328 1334
18. E. Vidor, B. Fritzell, S. Plotkin Clinical development of a new inactivated hepatitis A vaccine Infection 24 1996 447 458
19. P. Van Damme, S. Thoelen, M. Cramm, K. de Groote, A. Safary, A. Meheus Inactivated hepatitis A vaccine reactogenicity, immunogenicity, and long-term antibody persistence J Med Virol 44 1994 446 451
20. C.H. Hoke Jr, L.N. Binn, J.E. Egan Hepatitis A in the US Army epidemiology and vaccine development Vaccine 10 suppl 1 1992 S75 S79
21. S. Fujiyama, K. Odoh, I. Kuramoto, K. Mizuno, R. Tsurusaki, T. Sato Current seroepidemiological status of hepatitis A with a comparison of antibody titers after infection and vaccination J Hepatol 21 1994 641 645
22. Y.C. Horng, M.H. Chang, C.Y. Lee, A. Safary, F.E. Andre, D.S. Chen Safety and immunogenicity of hepatitis A vaccine in healthy children Pediatr Infect Dis J 12 1993 359 362
23. R. Clemens, A. Safary, A. Hepburn, C. Roche, W.J. Stanbury, F.E. Andre Clinical experience with an inactivated hepatitis A vaccine J Infect Dis 171 suppl 1 1995 S44 S49
24. D.R. Nalin VAQTA™, hepatitis A vaccine, purified inactivated Drugs Future 20 1995 24 29
25. B.J. McMahon, J. Williams, L. Bulkow Immunogenicity of an inactivated hepatitis A vaccine in Alaska native children and native and non-native adults J Infect Dis 171 1995 676 679
26. K.B. Balcarek, M.R. Bagley, R.F. Pass, E.R. Schiff, D.S. Krause Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children J Infect Dis 171 suppl 1 1995 S70 S72
27. S.D. Lee, K.J. Lo, C.Y. Chan, M.Y. Yu, Y.J. Wang, A. Safary Immunogenicity of inactivated hepatitis A vaccine in children Gastroenterology 104 1993 1129 1132
28. D. Nalin, L. Brown, B. Kuter Inactivated hepatitis A vaccine in childhood implications for disease control Vaccine 11 suppl 1 1993 S15 S17
29. S.L. Block, J.A. Hedrick, R.D. Tyler Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children Pediatr Infect Dis J 12 1993 976 980
30. A. Werzberger, B. Kuter, D. Shouval Anatomy of a trial a historical view of the Monroe inactivated hepatitis A protective efficacy trial J Hepatol 18 suppl 2 1993 S46 S50
31. G. Wiedermann, M. Kundi, F. Ambrosch, A. Safary, E. D'Hondt, A. Delem Inactivated hepatitis A vaccine long-term antibody persistence Vaccine 15 1997 612 615
32. D. Patel, J. Butler, S. Feldman, G.R. Graves, P.G. Rhodes Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants J Pediatr 130 1997 641 643
33. ®) with corresponding monovalent vaccines (Havrix® and Engerix-B®) in adults Vaccine 19 2001 4710 4719
34. P. Van Damme, G. Leroux-Roels, B. Law Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults J Med Virol 65 2001 6 13
35. E.B. Keeffe, S. Iwarson, B.J. McMahon Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease Hepatology 27 1998 881 886
36. M.R. Arguedas, A. Johnson, M.A. Eloubeidi, M.B. Fallon Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients Hepatology 34 2001 28 31
37. E.B. Keeffe Vaccination against hepatitis A and B in chronic liver disease Viral Hepat Rev 5 1999 77 88
38. E.B. Keeffe, D.S. Krause Hepatitis B vaccination of patients with chronic liver disease [letter] Liver Transpl Surg 4 1998 437 439
39. S.D. Lee, C.Y. Chan, M.I. Yu, R.H. Lu, F.Y. Chang, K.J. Lo Hepatitis B vaccination in patients with chronic hepatitis C J Med Virol 59 1999 463 468
40. N. De Maria, R. Idilman, A. Colantoni, D.H. Van Thiel Increased effective immunogenicity to high-dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis J Viral Hepat 8 2001 372 376
41. R. Idilman, N. De Maria, A. Colantoni, A. Nadir, D.H. Van Thiel The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C Am J Gastroenterol 97 2002 435 439
42. M. Dominguez, R. Barcena, M. Garcia, A. Lopez-Sanroman, J. Nuno Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list Liver Transplantation 6 2000 440 442
43. E.B. Keeffe Acute hepatitis A and B in patients with chronic liver disease prevention through vaccination Am J Med 118 suppl 10A 2005 21S 27S
44. J. Kahn Preventing hepatitis A and hepatitis B virus infections among men who have sex with men Clin Infect Dis 35 2002 1382 1387
45. G. Hess, R. Clemens, U. Bienzle, C. Schönfeld, B. Schunck, H.L. Bock Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men J Med Virol 46 1995 40 42
46. C.A. Carne, I.V.D. Weller, J. Waite Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine Br Med J (Clin Res Ed) 294 1987 866 868
47. A.C. Collier, L. Corey, V.L. Murphy, H.H. Handsfield Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination Ann Intern Med 109 1988 101 105
48. R.H.T. Loke, I.M. Murray-Lyon, J.C. Coleman, B.A. Evans, A.J. Zuckerman Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody an indicator of poor prognosis J Med Virol 31 1990 109 111
49. + lymphocyte count and vaccination schedule Int J STD AIDS 7 1996 490 494
50. E.H. Fleischmann, J. Kruppenbacher, H.L. Bock, M. Weber Active immunization against hepatitis A in dialysis patients Nephrol Dial Transplant 17 2002 1825 1828
51. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients MMWR Recomm Rep 50 RR-5 2001 1 43
52. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 45 RR-15 1996 1 30
53. Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 59. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2004. Available at: http://www.cdc.gov/ncidod/ diseases/hepatitis/resource/PDFs/hep_surveillance_59.pdf. Accessed June 8, 2005.
54. B.J. McMahon, M. Beller, J. Williams, M. Schloss, H. Tanttila, L. Bulkow A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine Arch Pediatr Adolesc Med 150 1996 733 739
55. F. Averhoff, C. Shapiro, I. Hyams Use of inactivated hepatitis A vaccine to interrupt a communitywide hepatitis A outbreak 1996 Presented at: 36th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. September 15-18,. Abstract H073
56. A.S. Craig, D.C. Sockwell, W. Schaffner Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A Clin Infect Dis 27 1998 531 535
57. B.A. Connor Hepatitis A vaccine in the last-minute traveler Am J Med. 118 suppl 10A 2005 58S 62S
58. Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP) inactivated hepatitis B virus vaccine MMWR Morb Mortal Wkly Rep 31 1982 317 322 327-328
59. Centers for Disease Control and Prevention Recommendations for protection against viral hepatitis MMWR Morb Mortal Wkly Rep 34 1985 313 324 329-335
60. Centers for Disease Control and Prevention Update on hepatitis B prevention MMWR Morb Mortal Wkly Rep 36 1987 353 366
61. Centers for Disease Control and Prevention Prevention of perinatal transmission of hepatitis B virus prenatal screening of all pregnant women for hepatitis B surface antigen MMWR Morb Mortal Wkly Rep 37 1988 341 346 351
62. Centers for Disease Control and Prevention Immunization of adolescents recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association MMWR Recomm Rep 45 RR-13 1996 1 16
63. Centers for Disease Control and Prevention Update recommendations to prevent hepatitis B virus transmission - United States MMWR Morb Mortal Wkly Rep 48 1999 33 34
64. G.A. Poland Evaluating existing recommendations for hepatitis A and B vaccination Am J Med. 118 suppl 10A 2005 16S 20S
65. Centers for Disease Control and Prevention. Combination vaccines for childhood immunization MMWR Recomm Rep 48 RR-5 1999 1 14